Business Description
ACADIA Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0042251084
Share Class Description:
ACAD: Ordinary SharesTotal Employee Number:
798Description
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16.76 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | 0.55 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.47 | |||||
Beneish M-Score | -1.16 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 25.4 | |||||
3-Year Book Growth Rate | 42.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.61 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.16 | |||||
9-Day RSI | 77.64 | |||||
14-Day RSI | 74.07 | |||||
3-1 Month Momentum % | -3.81 | |||||
6-1 Month Momentum % | -19.36 | |||||
12-1 Month Momentum % | 3.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.59 | |||||
Quick Ratio | 3.48 | |||||
Cash Ratio | 2.79 | |||||
Days Inventory | 112.87 | |||||
Days Sales Outstanding | 39.05 | |||||
Days Payable | 64.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.7 | |||||
Shareholder Yield % | -1.16 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 91.47 | |||||
Operating Margin % | 7.39 | |||||
Net Margin % | 34.3 | |||||
EBITDA Margin % | 8.46 | |||||
FCF Margin % | 19.4 | |||||
OCF Margin % | 11.28 | |||||
ROE % | 37.71 | |||||
ROA % | 27.39 | |||||
ROIC % | 20.03 | |||||
3-Year ROIIC % | 74.28 | |||||
ROC (Joel Greenblatt) % | 145.61 | |||||
ROCE % | 7.65 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.82 | |||||
Forward PE Ratio | 68.24 | |||||
PE Ratio without NRI | 11.82 | |||||
Price-to-Owner-Earnings | 14.2 | |||||
PS Ratio | 4.06 | |||||
PB Ratio | 3.56 | |||||
Price-to-Tangible-Book | 3.9 | |||||
Price-to-Free-Cash-Flow | 20.86 | |||||
Price-to-Operating-Cash-Flow | 35.69 | |||||
EV-to-EBIT | 45.13 | |||||
EV-to-Forward-EBIT | 67.74 | |||||
EV-to-EBITDA | 39.39 | |||||
EV-to-Forward-EBITDA | 62.05 | |||||
EV-to-Revenue | 3.33 | |||||
EV-to-Forward-Revenue | 2.96 | |||||
EV-to-FCF | 17.19 | |||||
Price-to-GF-Value | 1.03 | |||||
Price-to-Projected-FCF | 5.5 | |||||
Price-to-Median-PS-Value | 0.48 | |||||
Price-to-Graham-Number | 1.43 | |||||
| Price-to-Net-Current-Asset-Value | 6.02 | |||||
| Price-to-Net-Cash | 8.99 | |||||
Earnings Yield (Greenblatt) % | 2.22 | |||||
FCF Yield % | 4.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACAD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ACADIA Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,095.25 | ||
| EPS (TTM) ($) | 2.2 | ||
| Beta | 1.1706 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.34 | ||
| Volatility % | 34.45 | ||
| 14-Day RSI | 74.07 | ||
| 14-Day ATR ($) | 0.872012 | ||
| 20-Day SMA ($) | 23.386 | ||
| 12-1 Month Momentum % | 3.24 | ||
| 52-Week Range ($) | 19.69 - 28.35 | ||
| Shares Outstanding (Mil) | 171.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ACADIA Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ACADIA Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | In 29 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 28 days | ||
| General meeting for 2026 | 2026-05-29 07:45 | 21.63 (+3.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 16:30 | 22.35 (-0.13%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 22.35 (-0.13%) | ||
| Guidance call for 2026 | 2026-03-17 08:00 | 21.39 (+1.66%) | ||
| Annual report for 2025 | 2026-02-26 | 24.97 (+1.34%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-25 16:30 | 24.59 (-1.80%) |
Show
Entries
ACADIA Pharmaceuticals Inc Frequently Asked Questions
What is ACADIA Pharmaceuticals Inc(ACAD)'s stock price today?
The current price of ACAD is $26.00. The 52 week high of ACAD is $28.35 and 52 week low is $19.69.
When is next earnings date of ACADIA Pharmaceuticals Inc(ACAD)?
The next earnings date of ACADIA Pharmaceuticals Inc(ACAD) is 2026-08-06 Est..
Does ACADIA Pharmaceuticals Inc(ACAD) pay dividends? If so, how much?
ACADIA Pharmaceuticals Inc(ACAD) does not pay dividend.
Guru Commentaries on NAS:ACAD
No articles.
Press Release
Articles on ACADIA Pharmaceuticals Inc
Headlines
See More- 1
Jun 26, 2026
Acadia rises as EU backs Rett syndrome therapy
Seeking Alpha • 10:22am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers